Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tri-I TDI

- PMLiVE

FDA gives Loxo breakthrough tag for second cancer drug

US regulatory body to expect a NDA for LOXO-292 in late 2019

- PMLiVE

Novartis sells off part of Sandoz portfolio

Swiss pharma giant will retain biosimilars

- PMLiVE

Genetic counsellors: the new healthcare influencers?

Blue Latitude Health explores the relationship between physicians and genetic counsellors, and the impact this has on turning precision medicine into a reality for oncology patients.

Blue Latitude Health

- PMLiVE

Shire claims US okay for HAE blockbuster-in-waiting

FDA approves Takhzyro as a preventative measure for HAE attacks

Mastering the precision medicine opportunity

The rise of precision medicine will transform the pharma business model, challenging the way we commercialise therapies. BLH Senior Consultant and precision medicine expert David Cooney, reveals how you can...

Blue Latitude Health

- PMLiVE

FDA clears Kyowa Kirin’s skin lymphoma therapy Poteligeo

Becomes the first drug approved to treat Sézary syndrome

Dovetail pilots new approach to joint working

Award-winning healthcare collaboration specialists Dovetail will this month pilot a new programme of workshops on improving joint working between industry and clinicians for the benefit of patients. The first meeting...

Dovetail

- PMLiVE

China’s BeiGene raises $903m from Hong Kong IPO

Mammoth debut might have exceeded $1bn but for market jitters

- PMLiVE

Immunology keeps Shire figures solid as Takeda takeover nears

Shire’s sales increased by 6% to $3.81bn

- PMLiVE

Pfizer CEO reckons rebates will disappear, and that’s a positive

The move also has the support of FDA Commissioner Scott Gottlieb

Collaborate to Survive

In a PM Live guest blog this month, Dovetail’s Director, Claire Munro argues that for companies to survive the raft of major changes affecting pharma, they need to get better...

Dovetail

- PMLiVE

Novartis follows Pfizer and freezes US prices this year

And still expects revenues to come in at the high end of expectations for 2018

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links